The question now is not if cannabis will become a Schedule III drug but when. At the end of 2025, President Donald Trump signed an executive order to accelerate the process of rescheduling cannabis under the Controlled Substances Act.

Loren Bonner

Change is challenging for many individuals—including health care professionals.

Lauren Howell, PharmD, MHA

Pharmacists in Delaware can now be reimbursed for a broad scope of patient care services within the state’s Medicaid program as well as with all commercial insurers in the state.

Loren Bonner

A decision from February 13, 2026, by the United States Court of Appeals for the Fifth Circuit provides a rare opportunity for celebration.

David B. Brushwood, BSPharm, JD

Updates from FDA

APhA Staff

In January 2026, Novo Nordisk launched a new pill form of Wegovy, making it the first and only oral GLP-1 receptor agonist on the market for weight loss in adults with obesity.

Elizabeth Briand

For decades, vaccine recommendations issued by CDC’s ACIP have served as the backbone of immunization guidance in the United States. Clinicians have relied on the committee’s evidence-based process to guide conversations with patients and ensure consistent vaccine recommendations nationwide.

Sonya Collins

Slow tapering plus psychological support may be effective for preventing remitted depression relapse, according to a study published in the January 2026 issue of The Lancet Psychiatry.

Elizabeth Briand

Dandelion supplements are promoted for many potential health benefits due to the rich antioxidant, anti-inflammatory, and prebiotic content of the leaf, flower, and roots.

Mickie Cathers

In October 2025, Lingo (Abbott), became the first OTC CGM to be available for purchase in some retail stores.

Lauren Howell, PharmD, MHA

The American Pharmacists Association established these special awards in 2008 to recognize the value and extraordinary contributions pharmacists provide to improving the vaccination rates in their communities.

APhA Staff

Multiple myeloma is characterized by progressive immune dysfunction and multiple relapses, and off-the-shelf highly effective regimens are needed to fully address the needs of individual patients with relapsed or refractory multiple myeloma.

APhA Staff

Febrile neutropenia continues to challenge oncology teams despite decades of clinical experience.

Aiya Almogaber, PharmD

Cardiovascular disease is the leading cause of death in people with end-stage kidney disease, but there are few means of prevention.

Sonya Collins

Medication nonadherence remains a common challenge in patient care.

Emily Weyenberg, PharmD

Leaving a pharmacist out of a palliative care team is like trying to drive a car with a missing tire, said Rabia S. Atayee, PharmD.

Jen Hand

FDA approved 46 new (“novel”) drugs in 2025 that had not been approved or marketed in the United States.

Mark S. Johnson, PharmD, MACE, BCPS

APhA Member News

APhA staff

Take the Crossword Challenge